Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Exelixis
Description:
Renal cell carcinoma (RCC) is a kidney cancer that originates in the
lining of the proximal convoluted tubule, a part of the very small
tubes in the kidney that transport waste molecules from the blood to
the urine. RCC is the most common type of kidney cancer in adults,
responsible for approximately 90–95% of cases. In 2022, it is
estimated that there will be approximately 76,080 new cases of
kidney cancer, and about 13,780 people will die from the disease.
Approximately 16% of patients with RCC will have metastases at
diagnosis, and as many as 40% will demonstrate metastasis after
primary surgical treatment for localized RCC. With a 5-year survival
rate ranging from 5% to 12%, the prognosis for these patients is
poor. Fortunately for patients with advanced RCC, several new
treatments, including targeted therapies and immunotherapies, have
recently become available giving clinicians new options to improve
patient outcomes and quality of life. Additionally, new combination
regimens comprised of multiple receptor tyrosine kinase inhibitors
and anti-PD-1 immunotherapies have shown improved efficacy and
safety in clinical trials. With so many new options becoming
available for the healthcare community, clinicians are struggling to
stay abreast of all the changes in advanced RCC treatment. It is
critical that medical directors, oncologists, nurses and other
healthcare professionals are updated on these emerging options and
strategies for implementing them into the treatment paradigm, which
will ultimately improve patient outcomes.
Upon completion of this
activity, participants will be able to:
-
Assess the clinical and economic
burden of renal cell carcinoma (RCC), including factors that
contribute to poor prognosis and increased costs
-
Explain considerations for selecting
a first-line treatment regimen for a patient with advanced RCC,
including biomarkers, adverse events, and medical comorbidities
-
Analyze the evolving role of TKI and
immunotherapy combinations in the first-line management of
advanced RCC
-
Identify patients with advanced RCC
who might benefit from treatment with TKI and immunotherapy
combinations based on current evidence and guideline updates
-
Discuss modifications for drug
therapy for toxicity management in patients receiving treatment
for advanced RCC with an TKI and immunotherapy combination based
on expert recommendations
-
Evaluate the managed care
considerations of current and emerging TKI and immunotherapy
combinations by exploring where these agents fit in the current
RCC management paradigm
|
Faculty: |
Neeraj Agarwal, MD
Professor of Medicine
Huntsman Cancer Institute (HCI) Presidential Endowed
Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC) |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Neeraj Agarwal, MD has served as a consultant for Aveo,
Exelixis, Genentech, Gilead, Lilly, and Merck. His
presentation has been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
Exelixis
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |